Telomir Pharmaceuticals, Inc. Operating Expenses
Telomir Pharmaceuticals, Inc. (TELO) reported Operating Expenses of $1.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $1.76M, a 65.19% decline year-over-year.
- Telomir Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $1.04M, a 52.40% decline year-over-year.
- Telomir Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $2.13M, a 26.53% decline year-over-year.
- Telomir Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $1.15M, a 80.91% decline year-over-year.
- Telomir Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $10.54M, a 13.91% decline from fiscal 2024.
- Telomir Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $12.24M, a 210.55% increase from fiscal 2023.
- Telomir Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $3.94M, a 361.52% increase from fiscal 2022.
- Telomir Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $854.15K.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.76M 10-Q · filed 2026-08-13 | $2.81M 10-Q · filed 2026-08-13 | $4.94M derived: sum of 3 quarters · filed 2026-08-13 | $6.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.04M 10-Q · filed 2026-05-14 | $3.18M derived: sum of 2 quarters · filed 2026-05-14 | $4.32M derived: sum of 3 quarters · filed 2026-05-14 | $9.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.28M derived: sum of 2 quarters · filed 2026-03-17 | $8.35M derived: sum of 3 quarters · filed 2026-08-13 | $10.54M 10-K · filed 2026-03-17 |
| 2025-09-30 | $1.15M 10-Q · filed 2025-11-10 | $6.22M derived: sum of 2 quarters · filed 2026-08-13 | $8.40M 10-Q · filed 2025-11-10 | $11.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $5.07M 10-Q · filed 2026-08-13 | $7.26M 10-Q · filed 2026-08-13 | $10.16M derived: sum of 3 quarters · filed 2026-08-13 | $16.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.19M 10-Q · filed 2026-05-14 | $5.09M derived: sum of 2 quarters · filed 2026-05-14 | $11.10M derived: sum of 3 quarters · filed 2026-05-14 | $12.57M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $8.91M derived: sum of 2 quarters · filed 2026-03-17 | $10.39M derived: sum of 3 quarters · filed 2026-03-17 | $12.24M 10-K · filed 2026-03-17 |
| 2024-09-30 | $6.01M 10-Q · filed 2025-11-10 | $7.48M derived: sum of 2 quarters · filed 2025-11-10 | $9.34M 10-Q · filed 2025-11-10 | $10.48M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.47M 10-Q · filed 2025-08-14 | $3.39M 10-Q · filed 2025-08-14 | $4.47M derived: sum of 3 quarters · filed 2025-08-14 | $5.42M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.92M 10-Q · filed 2025-05-14 | $2.99M derived: sum of 2 quarters · filed 2025-05-14 | $3.95M derived: sum of 3 quarters · filed 2025-05-14 | $5.38M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | $2.03M derived: sum of 2 quarters · filed 2025-02-04 | $3.46M derived: sum of 3 quarters · filed 2025-02-04 | $3.94M 10-K · filed 2025-02-04 |
| 2023-09-30 | $954.15K 10-Q · filed 2024-11-12 | $2.38M derived: sum of 2 quarters · filed 2024-11-12 | $2.86M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.43M 10-Q · filed 2024-08-13 | $1.91M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $482.94K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $854.15K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |